Sirnaomics Ltd.

About Sirnaomics Ltd.

Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company focused on discovering and developing innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. Founded in 2007 in Gaithersburg, Maryland, the company operates in both the U.S. and Greater China, aiming to become a fully-integrated international biopharmaceutical entity leveraging its deep experience in RNA therapeutics and novel delivery platform technologies.

Products & Services

STP705:An RNAi therapeutic in development for oncology (e.g., cutaneous basal cell carcinoma, squamous cell carcinoma), medical aesthetics (e.g., focal fat reduction), and other skin conditions.

STP707:An RNAi therapeutic targeting solid tumors, liver fibrosis in primary sclerosing cholangitis, and pancreatic cancer.

GalAhead™ Platform:A GalNAc-based liver-targeting RNAi therapeutic platform with multiple candidates (e.g., STP122G for anticoagulant treatment, STP125G targeting ApoC3 for cardiovascular diseases).

RV-1730:A COVID-19 booster vaccine under development by RNAimmune, a related entity.

Polypeptide Nanoparticle Platform (PNP):A delivery platform primarily used for mRNA vaccines and therapeutics.

Specialties

RNA Therapeutics RNAi (RNA Interference) Technology mRNA Vaccines Drug Delivery Systems (GalNAc and PNP Platforms) Oncology Medical Aesthetics Antiviral Treatments Cardiometabolic Diseases Fibrosis-Related Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Strategic Equity Investment T: - FT: Strategic Equity Investment	A: 138000000 MR: - FA: HKD 138 million FAN: 138000000	D: 2025-09-07 FD: 2025-09-07	1 investors
2	RT: Equity Subscription T: - FT: Equity Subscription	A: 7572493 MR: - FA: HK$58.9 million FAN: 7572493	D: 2024-10-04 FD: 2024-10-04	1 investors
3	RT: Subsidy T: - FT: Subsidy	A: 1020800 MR: - FA: HK$8 million FAN: 1020800	D: 2023-05-17 FD: 2023-05-17	1 investors

Strategic Equity Investment Latest

2025-09-07

$138.0M

1 investor (Pro only)

Equity Subscription 2024-10-04

$7.6M

Subsidy 2023-05-17

$1.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

X

Xiaochang Dai

Executive Director & CSO

P

Patrick Lu

CEO

F

Francois Lebel

Chief Medical Officer

Recent News

Sirnaomics Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised